Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine in Ultra-Resistant Depression
NCT05137938Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Center for Addiction and Mental Health. Primary endpoint: Hamilton Rating Scale for Depression - 24 Items at 2 months. Started Oct 2021; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05137938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137938.